董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eliyahu Haddad | 男 | Chief Executive Officer and Director | 59 | 52.53万美元 | 10505.66 | 2026-09-16 |
| Moshe Shvets | 男 | Chief Technology Officer and Director | 61 | 49.66万美元 | 10537.87 | 2026-09-16 |
| Chaim Ravad | 男 | Director | 60 | 5.50万美元 | 4880.22 | 2026-09-16 |
| Yehuda Englander | 男 | Director | 45 | 4.03万美元 | 639.84 | 2026-09-16 |
| Chaim Hurvitz | 男 | Chairman of the Board and Director | 65 | 17.09万美元 | 6892.22 | 2026-09-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eliyahu Haddad | 男 | Chief Executive Officer and Director | 59 | 52.53万美元 | 10505.66 | 2026-09-16 |
| Moshe Shvets | 男 | Chief Technology Officer and Director | 61 | 49.66万美元 | 10537.87 | 2026-09-16 |
| Ran Israeli | 男 | Chief Financial Officer | 55 | 未披露 | 未持股 | 2026-09-16 |
董事简历
中英对照 | 中文 | 英文- Eliyahu Haddad
-
Eliyahu Haddad自2023年8月起担任Dror Ortho Design，Inc.的首席执行官和董事（Haddad先生还曾担任Dror Ortho Design，Inc.的首席财务官和首席会计官至2026年4月30日），并自2021年12月起担任Private Dror的首席执行官。Haddad先生是一位多学科的金融和技术专家，在筹集资金、发展复杂的商业模式以及指导初创公司和后期公司成功退出方面拥有丰富的高级运营经验。在受雇于Dror之前，Haddad先生曾在2007年至2021年期间担任HFT Investments的首席执行官。他还在2019年至2023年期间担任Exceed Talent Capital的高级顾问。在30年的职业生涯中，哈达德构建并管理了多项技术和媒体交易，总价值超过850亿美元，其中包括以色列高科技领域在人工智能、医疗技术和网络安全领域的2.5亿美元交易。Haddad先生获得了哥伦比亚大学经济学和哲学学士学位，并获得了美国国家科学基金会理论物理学奖，并在摩根士丹利媒体和技术集团的并购子集团开始了几年的职业生涯。
Eliyahu Haddad has served as Dror Ortho Design, Inc.'s Chief Executive Officer and director since August 2023 (with Mr. Haddad also having served as Dror Ortho Design, Inc.'s Principal Financial Officer and Principal Accounting Officer through April 30, 2026) and has served as Chief Executive Officer of Private Dror since December 2021. Mr. Haddad is a multi disciplinary finance and technology expert, with extensive senior level operational experience in raising capital, growing complex business models, and guiding startups and later stage companies to successful exits. Prior to his employment at Dror, Mr. Haddad served as Chief Executive Officer of HFT Investments from 2007 through 2021. He also served as a Senior Adviser at Exceed Talent Capital between 2019 and 2023. Over the course of his 30 year career, Mr. Haddad has structured and managed a number of technology and media transactions valued at an aggregate of over $85 billion, including $250 million in transactions within the Israeli high tech space in AI, medical technology, and cybersecurity. Mr. Haddad received a bachelor's degree in economics and philosophy from Columbia University, where he was the recipient of the National Science Foundation Award in Theoretical Physics and started his career in the M&A subgroup of Morgan Stanley's media and technology group for several years. - Eliyahu Haddad自2023年8月起担任Dror Ortho Design，Inc.的首席执行官和董事（Haddad先生还曾担任Dror Ortho Design，Inc.的首席财务官和首席会计官至2026年4月30日），并自2021年12月起担任Private Dror的首席执行官。Haddad先生是一位多学科的金融和技术专家，在筹集资金、发展复杂的商业模式以及指导初创公司和后期公司成功退出方面拥有丰富的高级运营经验。在受雇于Dror之前，Haddad先生曾在2007年至2021年期间担任HFT Investments的首席执行官。他还在2019年至2023年期间担任Exceed Talent Capital的高级顾问。在30年的职业生涯中，哈达德构建并管理了多项技术和媒体交易，总价值超过850亿美元，其中包括以色列高科技领域在人工智能、医疗技术和网络安全领域的2.5亿美元交易。Haddad先生获得了哥伦比亚大学经济学和哲学学士学位，并获得了美国国家科学基金会理论物理学奖，并在摩根士丹利媒体和技术集团的并购子集团开始了几年的职业生涯。
- Eliyahu Haddad has served as Dror Ortho Design, Inc.'s Chief Executive Officer and director since August 2023 (with Mr. Haddad also having served as Dror Ortho Design, Inc.'s Principal Financial Officer and Principal Accounting Officer through April 30, 2026) and has served as Chief Executive Officer of Private Dror since December 2021. Mr. Haddad is a multi disciplinary finance and technology expert, with extensive senior level operational experience in raising capital, growing complex business models, and guiding startups and later stage companies to successful exits. Prior to his employment at Dror, Mr. Haddad served as Chief Executive Officer of HFT Investments from 2007 through 2021. He also served as a Senior Adviser at Exceed Talent Capital between 2019 and 2023. Over the course of his 30 year career, Mr. Haddad has structured and managed a number of technology and media transactions valued at an aggregate of over $85 billion, including $250 million in transactions within the Israeli high tech space in AI, medical technology, and cybersecurity. Mr. Haddad received a bachelor's degree in economics and philosophy from Columbia University, where he was the recipient of the National Science Foundation Award in Theoretical Physics and started his career in the M&A subgroup of Morgan Stanley's media and technology group for several years.
- Moshe Shvets
-
Moshe Shvets自2023年8月起担任董事兼首席技术官，自2020年7月起担任Private DROR首席技术官，自2022年1月起担任Private DROR高级副总裁。Shvets先生还自2021年12月1日起担任高级副总裁。Shvets先生是一位经验丰富的高级管理人员，在建立年收入超过2.5亿欧元的公司方面拥有25年的经验，这些公司涉及复杂的仪器仪表和流程、监管、软件和全球基础设施。在加入Dror之前，Shvets先生于2015年至2018年创立BiSec Ltd.并担任董事。Shvets先生还曾于2011年至2013年担任OAO Belzan总裁，并于2011年至2014年担任OAO DZV总裁。在加入管理团队之前，Shvets先生是Dror Ortho Design，Inc.公司的投资者之一。Shvets先生于1999年获得圣彼得堡国立大学航空航天仪器学士学位。
Moshe Shvets has served as a director and Chief Technology Officer since August 2023, Chief Technology Officer of Private Dror since July 2020 and Senior Vice President of Private Dror since January 2022. Mr. Shvets has also served as a Senior Vice President since December 1, 2021. Mr. Shvets is a seasoned senior executive with 25 years of experience in building companies with over 250M yearly revenues that involve complex instrumentation & processes, regulation, software, and global infrastructure. Prior to joining Dror, Mr. Shvets founded and served as a director of BiSec Ltd. from 2015 to 2018. Mr. Shvets has also served as president of OAO Belzan from 2011 to 2013, and president of OAO DZV from 2011 to 2014. Before joining the management team, Mr. Shvets was one of the investors in Dror Ortho Design, Inc.'s Company. Mr. Shvets received a bachelor's degree from Saint Petersburg State University in Aerospace Instrumentation in 1999. - Moshe Shvets自2023年8月起担任董事兼首席技术官，自2020年7月起担任Private DROR首席技术官，自2022年1月起担任Private DROR高级副总裁。Shvets先生还自2021年12月1日起担任高级副总裁。Shvets先生是一位经验丰富的高级管理人员，在建立年收入超过2.5亿欧元的公司方面拥有25年的经验，这些公司涉及复杂的仪器仪表和流程、监管、软件和全球基础设施。在加入Dror之前，Shvets先生于2015年至2018年创立BiSec Ltd.并担任董事。Shvets先生还曾于2011年至2013年担任OAO Belzan总裁，并于2011年至2014年担任OAO DZV总裁。在加入管理团队之前，Shvets先生是Dror Ortho Design，Inc.公司的投资者之一。Shvets先生于1999年获得圣彼得堡国立大学航空航天仪器学士学位。
- Moshe Shvets has served as a director and Chief Technology Officer since August 2023, Chief Technology Officer of Private Dror since July 2020 and Senior Vice President of Private Dror since January 2022. Mr. Shvets has also served as a Senior Vice President since December 1, 2021. Mr. Shvets is a seasoned senior executive with 25 years of experience in building companies with over 250M yearly revenues that involve complex instrumentation & processes, regulation, software, and global infrastructure. Prior to joining Dror, Mr. Shvets founded and served as a director of BiSec Ltd. from 2015 to 2018. Mr. Shvets has also served as president of OAO Belzan from 2011 to 2013, and president of OAO DZV from 2011 to 2014. Before joining the management team, Mr. Shvets was one of the investors in Dror Ortho Design, Inc.'s Company. Mr. Shvets received a bachelor's degree from Saint Petersburg State University in Aerospace Instrumentation in 1999.
- Chaim Ravad
-
Chaim Ravad自2023年8月起担任董事，此前从2015年2月起担任Private Dror的董事，直至2023年8月股份交易所收盘。Ravad先生拥有食品餐饮和房地产行业的经验。作为Dror Ortho Design，Inc.的董事，Ravad先生从Dror牙齿矫正产品的早期阶段到获得FDA和CE批准之前，一直是该产品开发的主要贡献者，过去曾成功协助获得对Dror Ortho Design，Inc.公司的私人投资。Ravad先生毕业于Hebron Yeshiva。
Chaim Ravad has served as a director since August 2023 and previously served as a director of Private Dror from February 2015, until the closing of the Share Exchange in August 2023. Mr. Ravad has experience in food catering and real estate industries. In his capacity as Dror Ortho Design, Inc.'s director, Mr. Ravad has served as a major contributor to the development of Dror's teeth straightening product from its early stages and until receipt of FDA and CE approval and has in the past successfully assisted in securing private investments in Dror Ortho Design, Inc.'s Company. Mr. Ravad is a graduate of Hebron Yeshiva. - Chaim Ravad自2023年8月起担任董事，此前从2015年2月起担任Private Dror的董事，直至2023年8月股份交易所收盘。Ravad先生拥有食品餐饮和房地产行业的经验。作为Dror Ortho Design，Inc.的董事，Ravad先生从Dror牙齿矫正产品的早期阶段到获得FDA和CE批准之前，一直是该产品开发的主要贡献者，过去曾成功协助获得对Dror Ortho Design，Inc.公司的私人投资。Ravad先生毕业于Hebron Yeshiva。
- Chaim Ravad has served as a director since August 2023 and previously served as a director of Private Dror from February 2015, until the closing of the Share Exchange in August 2023. Mr. Ravad has experience in food catering and real estate industries. In his capacity as Dror Ortho Design, Inc.'s director, Mr. Ravad has served as a major contributor to the development of Dror's teeth straightening product from its early stages and until receipt of FDA and CE approval and has in the past successfully assisted in securing private investments in Dror Ortho Design, Inc.'s Company. Mr. Ravad is a graduate of Hebron Yeshiva.
- Yehuda Englander
-
Yehuda Englander自2023年8月起担任董事，此前自2021年12月起担任Private Dror的董事，直至2023年8月股份交易所收盘。Englander先生是YYE ALEY SHLECHT ASSETS LTD.和YE RUT Finance Ltd.的联合创始人。在此之前，Englander先生曾领导Yehuda Englander Finance Advisory Ltd.四年。Englander先生在耶路撒冷理工学院Lev学术中心获得会计学学士学位。
Yehuda Englander has served as a director since August 2023 and previously served as a director of Private Dror from December 2021, until the closing of the Share Exchange in August 2023. Mr. Englander is a co founder of YYE ALEY SHLECHT ASSETS LTD. and YE RUT Finance Ltd. Prior to that, Mr. Englander led Yehuda Englander Finance Advisory Ltd. for four years. Mr. Englander received a B.A. in Accounting from Lev Academic Center at Jerusalem College of Technology. - Yehuda Englander自2023年8月起担任董事，此前自2021年12月起担任Private Dror的董事，直至2023年8月股份交易所收盘。Englander先生是YYE ALEY SHLECHT ASSETS LTD.和YE RUT Finance Ltd.的联合创始人。在此之前，Englander先生曾领导Yehuda Englander Finance Advisory Ltd.四年。Englander先生在耶路撒冷理工学院Lev学术中心获得会计学学士学位。
- Yehuda Englander has served as a director since August 2023 and previously served as a director of Private Dror from December 2021, until the closing of the Share Exchange in August 2023. Mr. Englander is a co founder of YYE ALEY SHLECHT ASSETS LTD. and YE RUT Finance Ltd. Prior to that, Mr. Englander led Yehuda Englander Finance Advisory Ltd. for four years. Mr. Englander received a B.A. in Accounting from Lev Academic Center at Jerusalem College of Technology.
- Chaim Hurvitz
-
Chaim Hurvitz是Nrx Pharmaceuticals, Inc.董事会的成员，自2021年5月起担任该职务。他曾担任Nrx Pharmaceuticals, Inc.前身NeuroRx, Inc.的董事会成员，任期从2015年5月开始。自2011年5月起，Hurvitz先生担任CH Health的首席执行官，这是一家私人风险投资公司。在此之前，Hurvitz先生曾于2010年10月至2014年7月担任Teva Pharmaceuticals Industries Ltd.的董事会成员。此前，他曾是Teva Pharmaceuticals Industries Ltd.的高级管理层成员，从2002年至2010年担任Teva国际集团总裁，从1992年至1999年担任Teva Pharmaceuticals Europe总裁兼首席执行官，以及从1999年至2002年担任以色列制药销售副总裁。Hurvitz先生是Galmed Pharmaceuticals Ltd.的创始投资者和董事。他目前担任以色列制造商协会的管理成员，并担任其制药部门的负责人。Hurvitz先生拥有以色列特拉维夫大学的学士学位。
Chaim Hurvitz has served as a director and Chairman of Dror Ortho Design, Inc.'s Board since August 2023 and previously served as Chairman of Private Dror from January 17, 2012, until the closing of the Share Exchange in August 2023. Mr. Hurvitz has founded and has served as chief executive officer of C.H. Health, a healthcare focused venture capital firm since May 2011. His investments through CH Health have included several successful exits including the Nasdaq IPOs of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed") and UroGen Pharma Ltd. (NASDAQ: URGN) ("UroGen"). He was previously a member of Teva's senior management, serving as the President of Teva International Group from 2002 through 2010, Vice President of Israeli Pharmaceutical Sales from 1999 through 2002 and President and CEO of Teva Pharmaceuticals Europe from 1992 through 1999. Mr. Hurvitz presently serves as the chairman of Univo Pharmaceuticals Ltd., the chairman of Shirat Hachaim Ltd., a director of Celexir, a director of Genoscience Pharma S.A.S., and a director of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) and has previously served as the chairman CTG Weld Limited, as the chairman of PolyPid Ltd. (NASDAQ: PYPD), as the chairman of Galmed, as a director of UroGen, and as a director of Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Mr. Hurvitz is also a member of management of the Manufacturers Association of Israel and Head of its Pharmaceutical branch. Mr. Hurvitz received a B.A. in political science and economics from Tel Aviv University in 1985. - Chaim Hurvitz是Nrx Pharmaceuticals, Inc.董事会的成员，自2021年5月起担任该职务。他曾担任Nrx Pharmaceuticals, Inc.前身NeuroRx, Inc.的董事会成员，任期从2015年5月开始。自2011年5月起，Hurvitz先生担任CH Health的首席执行官，这是一家私人风险投资公司。在此之前，Hurvitz先生曾于2010年10月至2014年7月担任Teva Pharmaceuticals Industries Ltd.的董事会成员。此前，他曾是Teva Pharmaceuticals Industries Ltd.的高级管理层成员，从2002年至2010年担任Teva国际集团总裁，从1992年至1999年担任Teva Pharmaceuticals Europe总裁兼首席执行官，以及从1999年至2002年担任以色列制药销售副总裁。Hurvitz先生是Galmed Pharmaceuticals Ltd.的创始投资者和董事。他目前担任以色列制造商协会的管理成员，并担任其制药部门的负责人。Hurvitz先生拥有以色列特拉维夫大学的学士学位。
- Chaim Hurvitz has served as a director and Chairman of Dror Ortho Design, Inc.'s Board since August 2023 and previously served as Chairman of Private Dror from January 17, 2012, until the closing of the Share Exchange in August 2023. Mr. Hurvitz has founded and has served as chief executive officer of C.H. Health, a healthcare focused venture capital firm since May 2011. His investments through CH Health have included several successful exits including the Nasdaq IPOs of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed") and UroGen Pharma Ltd. (NASDAQ: URGN) ("UroGen"). He was previously a member of Teva's senior management, serving as the President of Teva International Group from 2002 through 2010, Vice President of Israeli Pharmaceutical Sales from 1999 through 2002 and President and CEO of Teva Pharmaceuticals Europe from 1992 through 1999. Mr. Hurvitz presently serves as the chairman of Univo Pharmaceuticals Ltd., the chairman of Shirat Hachaim Ltd., a director of Celexir, a director of Genoscience Pharma S.A.S., and a director of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) and has previously served as the chairman CTG Weld Limited, as the chairman of PolyPid Ltd. (NASDAQ: PYPD), as the chairman of Galmed, as a director of UroGen, and as a director of Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Mr. Hurvitz is also a member of management of the Manufacturers Association of Israel and Head of its Pharmaceutical branch. Mr. Hurvitz received a B.A. in political science and economics from Tel Aviv University in 1985.
高管简历
中英对照 | 中文 | 英文- Eliyahu Haddad
Eliyahu Haddad自2023年8月起担任Dror Ortho Design，Inc.的首席执行官和董事（Haddad先生还曾担任Dror Ortho Design，Inc.的首席财务官和首席会计官至2026年4月30日），并自2021年12月起担任Private Dror的首席执行官。Haddad先生是一位多学科的金融和技术专家，在筹集资金、发展复杂的商业模式以及指导初创公司和后期公司成功退出方面拥有丰富的高级运营经验。在受雇于Dror之前，Haddad先生曾在2007年至2021年期间担任HFT Investments的首席执行官。他还在2019年至2023年期间担任Exceed Talent Capital的高级顾问。在30年的职业生涯中，哈达德构建并管理了多项技术和媒体交易，总价值超过850亿美元，其中包括以色列高科技领域在人工智能、医疗技术和网络安全领域的2.5亿美元交易。Haddad先生获得了哥伦比亚大学经济学和哲学学士学位，并获得了美国国家科学基金会理论物理学奖，并在摩根士丹利媒体和技术集团的并购子集团开始了几年的职业生涯。
Eliyahu Haddad has served as Dror Ortho Design, Inc.'s Chief Executive Officer and director since August 2023 (with Mr. Haddad also having served as Dror Ortho Design, Inc.'s Principal Financial Officer and Principal Accounting Officer through April 30, 2026) and has served as Chief Executive Officer of Private Dror since December 2021. Mr. Haddad is a multi disciplinary finance and technology expert, with extensive senior level operational experience in raising capital, growing complex business models, and guiding startups and later stage companies to successful exits. Prior to his employment at Dror, Mr. Haddad served as Chief Executive Officer of HFT Investments from 2007 through 2021. He also served as a Senior Adviser at Exceed Talent Capital between 2019 and 2023. Over the course of his 30 year career, Mr. Haddad has structured and managed a number of technology and media transactions valued at an aggregate of over $85 billion, including $250 million in transactions within the Israeli high tech space in AI, medical technology, and cybersecurity. Mr. Haddad received a bachelor's degree in economics and philosophy from Columbia University, where he was the recipient of the National Science Foundation Award in Theoretical Physics and started his career in the M&A subgroup of Morgan Stanley's media and technology group for several years.- Eliyahu Haddad自2023年8月起担任Dror Ortho Design，Inc.的首席执行官和董事（Haddad先生还曾担任Dror Ortho Design，Inc.的首席财务官和首席会计官至2026年4月30日），并自2021年12月起担任Private Dror的首席执行官。Haddad先生是一位多学科的金融和技术专家，在筹集资金、发展复杂的商业模式以及指导初创公司和后期公司成功退出方面拥有丰富的高级运营经验。在受雇于Dror之前，Haddad先生曾在2007年至2021年期间担任HFT Investments的首席执行官。他还在2019年至2023年期间担任Exceed Talent Capital的高级顾问。在30年的职业生涯中，哈达德构建并管理了多项技术和媒体交易，总价值超过850亿美元，其中包括以色列高科技领域在人工智能、医疗技术和网络安全领域的2.5亿美元交易。Haddad先生获得了哥伦比亚大学经济学和哲学学士学位，并获得了美国国家科学基金会理论物理学奖，并在摩根士丹利媒体和技术集团的并购子集团开始了几年的职业生涯。
- Eliyahu Haddad has served as Dror Ortho Design, Inc.'s Chief Executive Officer and director since August 2023 (with Mr. Haddad also having served as Dror Ortho Design, Inc.'s Principal Financial Officer and Principal Accounting Officer through April 30, 2026) and has served as Chief Executive Officer of Private Dror since December 2021. Mr. Haddad is a multi disciplinary finance and technology expert, with extensive senior level operational experience in raising capital, growing complex business models, and guiding startups and later stage companies to successful exits. Prior to his employment at Dror, Mr. Haddad served as Chief Executive Officer of HFT Investments from 2007 through 2021. He also served as a Senior Adviser at Exceed Talent Capital between 2019 and 2023. Over the course of his 30 year career, Mr. Haddad has structured and managed a number of technology and media transactions valued at an aggregate of over $85 billion, including $250 million in transactions within the Israeli high tech space in AI, medical technology, and cybersecurity. Mr. Haddad received a bachelor's degree in economics and philosophy from Columbia University, where he was the recipient of the National Science Foundation Award in Theoretical Physics and started his career in the M&A subgroup of Morgan Stanley's media and technology group for several years.
- Moshe Shvets
Moshe Shvets自2023年8月起担任董事兼首席技术官，自2020年7月起担任Private DROR首席技术官，自2022年1月起担任Private DROR高级副总裁。Shvets先生还自2021年12月1日起担任高级副总裁。Shvets先生是一位经验丰富的高级管理人员，在建立年收入超过2.5亿欧元的公司方面拥有25年的经验，这些公司涉及复杂的仪器仪表和流程、监管、软件和全球基础设施。在加入Dror之前，Shvets先生于2015年至2018年创立BiSec Ltd.并担任董事。Shvets先生还曾于2011年至2013年担任OAO Belzan总裁，并于2011年至2014年担任OAO DZV总裁。在加入管理团队之前，Shvets先生是Dror Ortho Design，Inc.公司的投资者之一。Shvets先生于1999年获得圣彼得堡国立大学航空航天仪器学士学位。
Moshe Shvets has served as a director and Chief Technology Officer since August 2023, Chief Technology Officer of Private Dror since July 2020 and Senior Vice President of Private Dror since January 2022. Mr. Shvets has also served as a Senior Vice President since December 1, 2021. Mr. Shvets is a seasoned senior executive with 25 years of experience in building companies with over 250M yearly revenues that involve complex instrumentation & processes, regulation, software, and global infrastructure. Prior to joining Dror, Mr. Shvets founded and served as a director of BiSec Ltd. from 2015 to 2018. Mr. Shvets has also served as president of OAO Belzan from 2011 to 2013, and president of OAO DZV from 2011 to 2014. Before joining the management team, Mr. Shvets was one of the investors in Dror Ortho Design, Inc.'s Company. Mr. Shvets received a bachelor's degree from Saint Petersburg State University in Aerospace Instrumentation in 1999.- Moshe Shvets自2023年8月起担任董事兼首席技术官，自2020年7月起担任Private DROR首席技术官，自2022年1月起担任Private DROR高级副总裁。Shvets先生还自2021年12月1日起担任高级副总裁。Shvets先生是一位经验丰富的高级管理人员，在建立年收入超过2.5亿欧元的公司方面拥有25年的经验，这些公司涉及复杂的仪器仪表和流程、监管、软件和全球基础设施。在加入Dror之前，Shvets先生于2015年至2018年创立BiSec Ltd.并担任董事。Shvets先生还曾于2011年至2013年担任OAO Belzan总裁，并于2011年至2014年担任OAO DZV总裁。在加入管理团队之前，Shvets先生是Dror Ortho Design，Inc.公司的投资者之一。Shvets先生于1999年获得圣彼得堡国立大学航空航天仪器学士学位。
- Moshe Shvets has served as a director and Chief Technology Officer since August 2023, Chief Technology Officer of Private Dror since July 2020 and Senior Vice President of Private Dror since January 2022. Mr. Shvets has also served as a Senior Vice President since December 1, 2021. Mr. Shvets is a seasoned senior executive with 25 years of experience in building companies with over 250M yearly revenues that involve complex instrumentation & processes, regulation, software, and global infrastructure. Prior to joining Dror, Mr. Shvets founded and served as a director of BiSec Ltd. from 2015 to 2018. Mr. Shvets has also served as president of OAO Belzan from 2011 to 2013, and president of OAO DZV from 2011 to 2014. Before joining the management team, Mr. Shvets was one of the investors in Dror Ortho Design, Inc.'s Company. Mr. Shvets received a bachelor's degree from Saint Petersburg State University in Aerospace Instrumentation in 1999.
- Ran Israeli
冉以色列拥有超过25年的高级财务领导经验，曾担任过在以色列、欧洲、中国和美国运营的公共和私营公司的副首席执行官和首席财务官。最近，从2022年至今，Israel先生担任Kardan NV的副首席执行官兼首席财务官，该公司是一家在特拉维夫证券交易所（“TASE”）交易的荷兰注册上市公司，在那里他指导了价值约10亿新谢克尔的全球资产组合，并成功完成了与以色列机构实体的两个总计15亿新谢克尔的债务重组周期。此前，从2018年到2021年，他曾担任Arena Group的副首席执行官兼首席财务官，随后担任首席执行官，Arena Group是一家TASE上市房地产公司，拥有瑞士德国所有权，在那里他管理着10亿新谢克尔的资产基础，并带领公司度过了多个运营和财务危机。以色列先生拥有耶路撒冷希伯来大学金融专业MBA学位，持有以色列证券管理局的投资管理执照，并在希伯来大学完成高级董事培训。
Ran Israeli has over 25 years of senior financial leadership experience, having served as Deputy Chief Executive Officer and Chief Financial Officer of public and private companies operating across Israel, Europe, China, and the United States. Most recently, from 2022 until present, Mr. Israeli has served as Deputy Chief Executive Officer and Chief Financial Officer of Kardan NV, a Netherlands registered public company traded on the Tel Aviv Stock Exchange ("TASE"), where he directed a global asset portfolio valued at approximately NIS 1 billion and successfully completed two debt restructuring cycles totaling NIS 1.5 billion with Israeli institutional entities. Previously, from 2018 until 2021, he served as Deputy Chief Executive Officer and Chief Financial Officer, and subsequently as Chief Executive Officer, of Arena Group, a TASE listed real estate company with Swiss German ownership, where he managed a NIS 1 billion asset base and led the company through multiple operational and financial crises. Mr. Israeli holds an MBA with a Finance specialty from the Hebrew University of Jerusalem, holds an Investment Management License from the Israel Securities Authority, and has completed advanced directors training at the Hebrew University.- 冉以色列拥有超过25年的高级财务领导经验，曾担任过在以色列、欧洲、中国和美国运营的公共和私营公司的副首席执行官和首席财务官。最近，从2022年至今，Israel先生担任Kardan NV的副首席执行官兼首席财务官，该公司是一家在特拉维夫证券交易所（“TASE”）交易的荷兰注册上市公司，在那里他指导了价值约10亿新谢克尔的全球资产组合，并成功完成了与以色列机构实体的两个总计15亿新谢克尔的债务重组周期。此前，从2018年到2021年，他曾担任Arena Group的副首席执行官兼首席财务官，随后担任首席执行官，Arena Group是一家TASE上市房地产公司，拥有瑞士德国所有权，在那里他管理着10亿新谢克尔的资产基础，并带领公司度过了多个运营和财务危机。以色列先生拥有耶路撒冷希伯来大学金融专业MBA学位，持有以色列证券管理局的投资管理执照，并在希伯来大学完成高级董事培训。
- Ran Israeli has over 25 years of senior financial leadership experience, having served as Deputy Chief Executive Officer and Chief Financial Officer of public and private companies operating across Israel, Europe, China, and the United States. Most recently, from 2022 until present, Mr. Israeli has served as Deputy Chief Executive Officer and Chief Financial Officer of Kardan NV, a Netherlands registered public company traded on the Tel Aviv Stock Exchange ("TASE"), where he directed a global asset portfolio valued at approximately NIS 1 billion and successfully completed two debt restructuring cycles totaling NIS 1.5 billion with Israeli institutional entities. Previously, from 2018 until 2021, he served as Deputy Chief Executive Officer and Chief Financial Officer, and subsequently as Chief Executive Officer, of Arena Group, a TASE listed real estate company with Swiss German ownership, where he managed a NIS 1 billion asset base and led the company through multiple operational and financial crises. Mr. Israeli holds an MBA with a Finance specialty from the Hebrew University of Jerusalem, holds an Investment Management License from the Israel Securities Authority, and has completed advanced directors training at the Hebrew University.